Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabian Model

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Bioinformatics (Oxford, England)|August 10, 2002
Statistical process control for large scale microarray experimentsFabian Model, Thomas König, Christian Piepenbrock, et al.
Current Biology : CB|March 19, 2004
Differences in DNA methylation patterns between humans and chimpanzeesWolfgang Enard, Anne Fassbender, Fabian Model, et al.
Tissue Engineering|June 26, 2007
DNA methylation analysis as novel tool for quality control in regenerative medicineStephen Rapko, Udo Baron, Ulrich Hoffmüller, et al.
Statistical Methods in Medical Research|November 15, 2023
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomesSean Yiu, Qing Wang, Francois Mercier, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2022
Recurrent disability progression endpoints in multiple sclerosis clinical trialsAlexandra Bühler, Marcel Wolbers, Fabian Model, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 10, 2020
Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approachMichael C Donohue, Fabian Model, Paul Delmar, et al.
British Journal of Clinical Pharmacology|November 17, 2020
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIOEkaterina Gibiansky, Claire Petry, Francois Mercier, et al.
Journal of Central Nervous System Disease|September 18, 2024
Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatmentsErwan Muros-Le Rouzic, Yanic Heer, Sean Yiu, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Brain : a Journal of Neurology|September 10, 2019
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Shibeshih Belachew, Jerry S Wolinsky, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Bioinformatics (Oxford, England)|August 10, 2002
Statistical process control for large scale microarray experimentsFabian Model, Thomas König, Christian Piepenbrock, et al.
Current Biology : CB|March 19, 2004
Differences in DNA methylation patterns between humans and chimpanzeesWolfgang Enard, Anne Fassbender, Fabian Model, et al.
Tissue Engineering|June 26, 2007
DNA methylation analysis as novel tool for quality control in regenerative medicineStephen Rapko, Udo Baron, Ulrich Hoffmüller, et al.
Statistical Methods in Medical Research|November 15, 2023
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomesSean Yiu, Qing Wang, Francois Mercier, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2022
Recurrent disability progression endpoints in multiple sclerosis clinical trialsAlexandra Bühler, Marcel Wolbers, Fabian Model, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 10, 2020
Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approachMichael C Donohue, Fabian Model, Paul Delmar, et al.
British Journal of Clinical Pharmacology|November 17, 2020
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIOEkaterina Gibiansky, Claire Petry, Francois Mercier, et al.
Journal of Central Nervous System Disease|September 18, 2024
Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatmentsErwan Muros-Le Rouzic, Yanic Heer, Sean Yiu, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Brain : a Journal of Neurology|September 10, 2019
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Shibeshih Belachew, Jerry S Wolinsky, et al.
Pageof 3